BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30179888)

  • 21. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
    Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
    J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
    Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
    Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
    Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
    Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.
    Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma.
    Hallack Neto AE; Siqueira SA; Dulley FL; Chauobah A; Belesso M; Saboia R; Ruiz MA; Chamone DA; Pereira J
    Sao Paulo Med J; 2010 Jan; 128(1):14-7. PubMed ID: 20512275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of reverse transcriptase - Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO).
    Dcunha N; Sakhti D; Sigamani E; Chandramohan J; Korula A; George B; Manipadam MT; Pai R
    Indian J Pathol Microbiol; 2023; 66(4):714-719. PubMed ID: 38084521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue.
    Reinders J; Altenbuchinger M; Limm K; Schwarzfischer P; Scheidt T; Strasser L; Richter J; Szczepanowski M; Huber CG; Klapper W; Spang R; Oefner PJ
    Sci Rep; 2020 May; 10(1):7876. PubMed ID: 32398793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 30. [Analysis of bcl-6 protein expression and gene rearrangement in diffuse large B-cell lymphoma].
    Min DL; Xia HL; Zhou XY; Sun MH; Yang WT; Zhang TM; Zheng AH; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):327-31. PubMed ID: 16185497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of prognostic factors in patients with diffuse large B-cell lymphoma.
    Peng F; Guo L; Yao WK; Zheng Y; Liu Y; Duan XM; Wang YP
    Indian J Pathol Microbiol; 2017; 60(1):87-91. PubMed ID: 28195099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy.
    Hassan U; Mushtaq S; Mamoon N; Asghar AH; Ishtiaq S
    Asian Pac J Cancer Prev; 2012; 13(4):1341-7. PubMed ID: 22799329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.
    Coutinho R; Clear AJ; Owen A; Wilson A; Matthews J; Lee A; Alvarez R; Gomes da Silva M; Cabeçadas J; Calaminici M; Gribben JG
    Clin Cancer Res; 2013 Dec; 19(24):6686-95. PubMed ID: 24122791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
    Yao XX; Wang JF; Wang YH; Gao N
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.
    Tzankov A; Pehrs AC; Zimpfer A; Ascani S; Lugli A; Pileri S; Dirnhofer S
    J Clin Pathol; 2003 Oct; 56(10):747-52. PubMed ID: 14514777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
    Barton S; Hawkes EA; Wotherspoon A; Cunningham D
    Oncologist; 2012; 17(12):1562-73. PubMed ID: 23086691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
    El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
    Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.
    Shi QY; Feng X; Bao W; Ma J; Lv JH; Wang X; Rao Q; Shi QL
    J Neuropathol Exp Neurol; 2017 Nov; 76(11):942-948. PubMed ID: 29044419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
    J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.